首页> 外文期刊>Health >Influence of hyperbaric oxygenation treatment (HBOT) on clinical outcomes (recurrent myocardial infarction and survival rate) during five-year monitoring period after acute myocardial infarction
【24h】

Influence of hyperbaric oxygenation treatment (HBOT) on clinical outcomes (recurrent myocardial infarction and survival rate) during five-year monitoring period after acute myocardial infarction

机译:高压氧治疗(HBOT)对急性心肌梗死后五年监测期间临床结局(复发性心肌梗塞和生存率)的影响

获取原文
           

摘要

Surgical treatments of acute myocardial infarction (MI) possess a high clinical effectiveness, but there are fixed limitations, related to the patient’s state, which are limited by medical resources and organizational problems. The development of new medical technologies provides a better and effective non-surgical treatment of acute MI and increases long-term prognosis in this category of patients. The study aims to investigate the influence of hyperbaric oxygenation treatment on clinical outcomes (survival rate and recurrent myocardial infarction (rMI)) during the five-year period of monitoring. The study involved 697 patients who suffered from acute MI, having undergone the standard treatment. The patients were randomly divided into two groups: Group 1 (reference, n = 363); Group 2 (test, n = 334). Patients of Group 2 were given the traditional treatment, accompanied with HBOT (isopression for forty minutes at a working pressure of 0.03 MPa). HBOT was applied first through the fifth day following MI. The treatment course included six cycles, once per day. The clinical assessment was focused on clinical outcome: rMI and mortality related to cardiovascular events. HBOT application that accompanied the acute MI with traditional pharmacotherapy has been proved to reduce rMI within five years following inpatient discharge (rMI rate was 14% in the reference group and 5.4% in the test group, χ2 = 13.3, р
机译:急性心肌梗死(MI)的外科治疗具有很高的临床效果,但是与患者的状态有关,存在固定的局限性,受医疗资源和组织问题的限制。新医学技术的发展为急性心肌梗死提供了更好,更有效的非手术治疗,并增加了这类患者的长期预后。这项研究旨在调查高压氧治疗在五年监测期间对临床结果(存活率和复发性心肌梗塞(rMI))的影响。该研究纳入了接受标准治疗的697例急性MI患者。将患者随机分为两组:第一组(参考值,n = 363);第二组。第2组(测试,n = 334)。第2组患者接受了传统治疗,并伴有HBOT(在0.03 MPa的工作压力下压迫40分钟)。 MI后第一至第五天开始应用HBOT。治疗过程包括六个周期,每天一次。临床评估的重点是临床结局:rMI和与心血管事件相关的死亡率。事实证明,在急性心肌梗死伴传统药物疗法的情况下应用HBOT可降低住院病人出院后五年内的rMI(参考组的rMI率为14%,测试组的rMI率为5.4%,χ2= 13.3,р

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号